Disc Medicine (NASDAQ:IRON) COO Jonathan Yen-Wen Yu Sells 300 Shares of Stock

Disc Medicine, Inc. (NASDAQ:IRON) COO Jonathan Yen-Wen Yu sold 300 shares of the firm’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $72.50, for a total transaction of $21,750.00. Following the transaction, the chief operating officer directly owned 54,324 shares of the company’s stock, valued at $3,938,490. This represents a 0.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Jonathan Yen-Wen Yu also recently made the following trade(s):

• On Monday, June 22nd, Jonathan Yen-Wen Yu sold 9,700 shares of Disc Medicine stock. The shares were sold at an average price of $72.66, for a total transaction of $704,802.00.
• On Tuesday, June 16th, Jonathan Yen-Wen Yu sold 18,612 shares of Disc Medicine stock. The shares were sold at an average price of $69.19, for a total transaction of $1,287,764.28.

Disc Medicine Stock Down 1.8%

NASDAQ:IRON opened at $73.14 on Wednesday. The firm has a market capitalization of $2.79 billion, a P/E ratio of -11.05 and a beta of 0.93. Disc Medicine, Inc. has a 1-year low of $40.00 and a 1-year high of $99.50. The company’s fifty day moving average price is $69.01 and its 200-day moving average price is $70.63. The company has a debt-to-equity ratio of 0.04, a current ratio of 24.00 and a quick ratio of 24.00.

Disc Medicine (NASDAQ:IRON) last issued its earnings results on Tuesday, May 5th. The company reported ($1.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.62) by ($0.03). As a group, equities research analysts anticipate that Disc Medicine, Inc. will post -6.74 EPS for the current year.

Institutional Investors Weigh In On Disc Medicine

Institutional investors have recently modified their holdings of the business. Assenagon Asset Management S.A. lifted its holdings in Disc Medicine by 3,329.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 357,836 shares of the company’s stock valued at $28,416,000 after acquiring an additional 347,403 shares during the last quarter. Hudson Bay Capital Management LP acquired a new stake in Disc Medicine during the third quarter worth $6,752,000. SG Americas Securities LLC increased its stake in Disc Medicine by 161.9% during the fourth quarter. SG Americas Securities LLC now owns 21,122 shares of the company’s stock worth $1,677,000 after acquiring an additional 13,058 shares during the last quarter. Vanguard Group Inc. raised its position in Disc Medicine by 3.7% in the third quarter. Vanguard Group Inc. now owns 1,448,059 shares of the company’s stock valued at $95,688,000 after purchasing an additional 51,323 shares during the period. Finally, First Light Asset Management LLC purchased a new stake in Disc Medicine in the third quarter valued at $15,277,000. 83.70% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on IRON shares. Wedbush reiterated an “outperform” rating and set a $88.00 price objective on shares of Disc Medicine in a research note on Wednesday, June 10th. Wall Street Zen upgraded Disc Medicine from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. Morgan Stanley raised their target price on Disc Medicine from $80.00 to $85.00 and gave the stock an “overweight” rating in a report on Monday, June 15th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Disc Medicine in a research report on Monday, April 20th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $105.80.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.